Interested in possible use of CRISPR/Cas9 for internal research programs?
Interested in use of genetically modified cells in manufacturing? Including…
Do you provide any services which utilize CRISPR/Cas9 or cells or animals modified by the technology? Including…
Do you have an interest in animal health applications? Including…
Let’s schedule a meeting and discuss how ERS might be able to help you.
Your journey with CRISPR begins with a license from ERS Genomics.
Explore more news on CRISPR/Cas9 and how it can provide a leading edge in the highly competitive biotech sector.
Dublin, Ireland, January 5, 2023: ERS Genomics announced that its first Canadian patent, CA 2872241, with broad claims to compositions and methods of using CRISPR/Cas9 in humans, animals, plants, and microbes has been granted to the CVC group. CVC stands for University of California, University of Vienna, and Emmanuelle Charpentier and.
Read Full ArticleSan Diego, USA and Dublin, Ireland 8 December 2022, Crown Bioscience, Inc and ERS Genomics Limited (‘ERS’) have signed a global license agreement for access to the foundational CRISPR/Cas9 patent portfolio held by ERS, which provides the company full license to operate globally using CRISPR/Cas9 for gene editing. Crown.
Read Full ArticleDublin, Ireland, December 1, 2022: ERS Genomics Limited (‘ERS’) is pleased to announce a new license agreement with Cosmo Bio. This is a non-exclusive license agreement granting Japan’s Cosmo Bio access to the ERS CRISPR/Cas9 patent portfolio. ERS, co-founded by Dr. Emmanuelle Charpentier, 2020 Nobel Prize winner for gene-editing, provides.
Read Full Article